Advertising disclosure: we may earn a commission when you buy through links on this site. How we make money

HomeTrials › NCT06654219

Other · Not applicable · Recruiting now

Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia

NCT06654219 · Sponsor: The University of Texas Health Science Center, Houston

What this trial means for you

This study is recruiting now at 1 US site. It's studying see the official record for pulmonary aspiration.

Who can joinAll sexes, 18 Years and older
Healthy volunteersNo — diagnosis required
What you'd takesee the official record
Study length~6 months overall
Planned participants136
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

The purpose of this study is to determine if prolonged fasting from solids and transitioning to a CLD for 24 hours is protective to decrease RGC in patients on GLP-1 RAs presenting for upper endoscopy, to determine if prolonged fasting is associated with increased thirst, hunger and anxiety, To determine if signs and symptoms of nausea, vomiting, retching, abdominal bloating, and abdominal pain are present on the day of surgery, to see if there is any variability between preoperative gastric ultrasound assessment and volume of gastric contents visualized on upper endoscopy, to determine time of gastric emptying by serial Gastric ultrasonography (GUS) scans every 2 hours in subjects who presented with an initial at-risk scan, to determine the choice of anesthesia used based on preoperative GUS results, to determine if there were any adverse events recorded in this study group, to determine if duration of GLP-1 RA therapy has an association with residual gastric content (RGC). and to determine if dosing of GLP-1 RA has an association with RGC.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: * Patients taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) agonists * Undergoing upper endoscopy only - no colonoscopy due to prep Exclusion Criteria: * Previous gastric resection or bypass * Gastric band in situ * Previous fundoplication * Large hiatal hernia * Pregnant patients * Recent trauma * Inability to turn to the right lateral decubitus position. * Patients on erythromycin, metoclopramide, domperidone, opioids. * Gastroparesis previous

Study sites by state

Texas

  • The University of Texas Health Science Center at Houston — Houston · Recruiting now

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently — always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in .env to activate this form.)

Keep researching on StudyBackedHealth